CN113880908B - 纯化重组人血清白蛋白的融合蛋白的方法 - Google Patents
纯化重组人血清白蛋白的融合蛋白的方法 Download PDFInfo
- Publication number
- CN113880908B CN113880908B CN202110983902.1A CN202110983902A CN113880908B CN 113880908 B CN113880908 B CN 113880908B CN 202110983902 A CN202110983902 A CN 202110983902A CN 113880908 B CN113880908 B CN 113880908B
- Authority
- CN
- China
- Prior art keywords
- solution
- exchange chromatography
- fusion protein
- protein
- supernatant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 52
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 41
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 41
- 102000008100 Human Serum Albumin Human genes 0.000 title claims abstract description 22
- 108091006905 Human Serum Albumin Proteins 0.000 title claims abstract description 22
- 239000006228 supernatant Substances 0.000 claims abstract description 37
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 23
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 20
- 238000005571 anion exchange chromatography Methods 0.000 claims abstract description 13
- 238000005277 cation exchange chromatography Methods 0.000 claims abstract description 13
- 238000001556 precipitation Methods 0.000 claims abstract description 13
- 230000020477 pH reduction Effects 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims description 42
- 239000006167 equilibration buffer Substances 0.000 claims description 30
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- 239000003480 eluent Substances 0.000 claims description 22
- 239000012501 chromatography medium Substances 0.000 claims description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- 239000003929 acidic solution Substances 0.000 claims description 14
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 14
- 239000012149 elution buffer Substances 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 102000000588 Interleukin-2 Human genes 0.000 claims description 11
- 239000007983 Tris buffer Substances 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 10
- 239000012228 culture supernatant Substances 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 8
- 230000002779 inactivation Effects 0.000 claims description 8
- 239000002609 medium Substances 0.000 claims description 8
- 239000001632 sodium acetate Substances 0.000 claims description 8
- 235000017281 sodium acetate Nutrition 0.000 claims description 8
- 239000012670 alkaline solution Substances 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 7
- 239000003381 stabilizer Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical group [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 238000011118 depth filtration Methods 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 229910001424 calcium ion Inorganic materials 0.000 claims description 4
- 159000000007 calcium salts Chemical class 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 150000005846 sugar alcohols Chemical class 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 2
- -1 sulfopropyl Chemical group 0.000 claims description 2
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 claims description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims 1
- 239000002265 redox agent Substances 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 63
- 108090000623 proteins and genes Proteins 0.000 abstract description 63
- 238000000746 purification Methods 0.000 abstract description 30
- 239000012535 impurity Substances 0.000 abstract description 22
- 239000000047 product Substances 0.000 abstract description 11
- 230000008569 process Effects 0.000 abstract description 7
- 238000011160 research Methods 0.000 abstract description 6
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 44
- 238000011068 loading method Methods 0.000 description 32
- 239000011780 sodium chloride Substances 0.000 description 22
- 239000012460 protein solution Substances 0.000 description 16
- 239000000523 sample Substances 0.000 description 15
- 238000005406 washing Methods 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000010828 elution Methods 0.000 description 10
- 239000000945 filler Substances 0.000 description 9
- 230000014759 maintenance of location Effects 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 238000006386 neutralization reaction Methods 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 238000002305 strong-anion-exchange chromatography Methods 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000007853 buffer solution Substances 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 238000011067 equilibration Methods 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000012521 purified sample Substances 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 238000000825 ultraviolet detection Methods 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 239000012466 permeate Substances 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 238000012437 strong cation exchange chromatography Methods 0.000 description 4
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000011210 chromatographic step Methods 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000013019 capto adhere Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000008380 degradant Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Water Supply & Treatment (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110983902.1A CN113880908B (zh) | 2021-08-25 | 2021-08-25 | 纯化重组人血清白蛋白的融合蛋白的方法 |
| PCT/CN2021/121807 WO2023024214A1 (fr) | 2021-08-25 | 2021-09-29 | Procédé de purification d'une protéine de fusion de l'albumine sérique humaine recombinée |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110983902.1A CN113880908B (zh) | 2021-08-25 | 2021-08-25 | 纯化重组人血清白蛋白的融合蛋白的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113880908A CN113880908A (zh) | 2022-01-04 |
| CN113880908B true CN113880908B (zh) | 2024-05-14 |
Family
ID=79011496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110983902.1A Active CN113880908B (zh) | 2021-08-25 | 2021-08-25 | 纯化重组人血清白蛋白的融合蛋白的方法 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113880908B (fr) |
| WO (1) | WO2023024214A1 (fr) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5440018A (en) * | 1992-05-20 | 1995-08-08 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
| CN101240033A (zh) * | 2008-03-04 | 2008-08-13 | 无锡和邦生物科技有限公司 | 一种促胰岛素分泌肽与人血清白蛋白的融合蛋白及其制备方法 |
| CN101260145A (zh) * | 2008-04-11 | 2008-09-10 | 北京未名福源基因药物研究中心有限公司 | 一种重组人血清白蛋白及其融合蛋白的分离纯化工艺 |
| CN102911250A (zh) * | 2012-09-29 | 2013-02-06 | 浙江海正药业股份有限公司 | 酸性重组蛋白药物的纯化方法 |
| CN104974251A (zh) * | 2008-10-20 | 2015-10-14 | Abbvie公司 | 在抗体纯化过程中的病毒灭活 |
| CN110526982A (zh) * | 2018-05-23 | 2019-12-03 | 信立泰(成都)生物技术有限公司 | 一种人胰高血糖素样肽-1类似物融合蛋白的纯化方法 |
| CN110770251A (zh) * | 2017-04-20 | 2020-02-07 | 诺和诺德股份有限公司 | 纯化白蛋白融合蛋白的方法 |
| CN111484557A (zh) * | 2019-01-25 | 2020-08-04 | 武汉禾元生物科技股份有限公司 | 一种从基因工程水稻种子中分离纯化重组人血清白蛋白-表皮生长因子融合蛋白的方法 |
| CN112724259A (zh) * | 2020-11-16 | 2021-04-30 | 天津林达生物科技有限公司 | 人血清白蛋白与白介素2的融合蛋白及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE526227C2 (sv) * | 2002-05-15 | 2005-08-02 | North China Pharmaceutical Group | Metod för rening av rekombinant humant serumalbumin |
| US10563210B2 (en) * | 2014-10-30 | 2020-02-18 | Soonchunhyang University Industry Academy Cooperation Foundation | Method for producing interleukin-2 protein using methylotrophic yeast |
| CN112210002B (zh) * | 2020-10-15 | 2022-06-10 | 楚天源创生物技术(长沙)有限公司 | 重组人血清白蛋白的纯化方法 |
-
2021
- 2021-08-25 CN CN202110983902.1A patent/CN113880908B/zh active Active
- 2021-09-29 WO PCT/CN2021/121807 patent/WO2023024214A1/fr unknown
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5440018A (en) * | 1992-05-20 | 1995-08-08 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
| CN101240033A (zh) * | 2008-03-04 | 2008-08-13 | 无锡和邦生物科技有限公司 | 一种促胰岛素分泌肽与人血清白蛋白的融合蛋白及其制备方法 |
| CN101260145A (zh) * | 2008-04-11 | 2008-09-10 | 北京未名福源基因药物研究中心有限公司 | 一种重组人血清白蛋白及其融合蛋白的分离纯化工艺 |
| CN104974251A (zh) * | 2008-10-20 | 2015-10-14 | Abbvie公司 | 在抗体纯化过程中的病毒灭活 |
| CN102911250A (zh) * | 2012-09-29 | 2013-02-06 | 浙江海正药业股份有限公司 | 酸性重组蛋白药物的纯化方法 |
| CN110770251A (zh) * | 2017-04-20 | 2020-02-07 | 诺和诺德股份有限公司 | 纯化白蛋白融合蛋白的方法 |
| CN110526982A (zh) * | 2018-05-23 | 2019-12-03 | 信立泰(成都)生物技术有限公司 | 一种人胰高血糖素样肽-1类似物融合蛋白的纯化方法 |
| CN111484557A (zh) * | 2019-01-25 | 2020-08-04 | 武汉禾元生物科技股份有限公司 | 一种从基因工程水稻种子中分离纯化重组人血清白蛋白-表皮生长因子融合蛋白的方法 |
| CN112724259A (zh) * | 2020-11-16 | 2021-04-30 | 天津林达生物科技有限公司 | 人血清白蛋白与白介素2的融合蛋白及其用途 |
Non-Patent Citations (2)
| Title |
|---|
| Fractionation of the human plasma proteome for monoclonal antibody proteomics-based biomarker discovery;Andras Kovacs;Electrophoresis;第1916–1925页 * |
| 人血清白蛋白纯化技术研究进展;路秀玲, 苏志国;生物工程学报(第06期);第761-766页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113880908A (zh) | 2022-01-04 |
| WO2023024214A1 (fr) | 2023-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2816050C (fr) | Procede pour purifier un facteur stimulant les colonies de granulocytes humain de e. coli recombinant | |
| CN109929027B (zh) | 采用线性洗脱步骤的重组融合蛋白纯化方法 | |
| US20170152298A1 (en) | Process for the purification of tnfr:fc fusion protein | |
| WO2011015926A1 (fr) | Procédé de fermentation, de purification et de production dune protéine hybride soluble de recombinaison du récepteur du facteur de nécrose tumorale alpha (tnfr) - domaine fc de ligg humaine | |
| CN102911250B (zh) | 酸性重组蛋白药物的纯化方法 | |
| CN101260145B (zh) | 一种重组人血清白蛋白及其融合蛋白的分离纯化工艺 | |
| JP2017526649A (ja) | ｒＨｕ−ＧＣＳＦの精製のための新規プロセス | |
| CN102850450B (zh) | 聚乙二醇化重组人粒细胞集落刺激因子的纯化方法 | |
| CN113880908B (zh) | 纯化重组人血清白蛋白的融合蛋白的方法 | |
| CN109929038B (zh) | Vegf捕获剂融合蛋白的纯化方法 | |
| WO2020078254A1 (fr) | Procédé d'isolement d'une hormone de croissance humaine recombinée à partir de graines de riz génétiquement modifié et purification associée | |
| CN110724204B (zh) | Fc融合蛋白的纯化方法 | |
| CN110590931B (zh) | 去除和/或灭活重组人血小板生成因子原液中病毒的方法 | |
| CN116199768B (zh) | 高纯度植物源重组人血清白蛋白的制备方法及其应用 | |
| EP0446850B1 (fr) | Procédé de purification de l'interféron bêta humain recombinant | |
| WO2011015919A1 (fr) | Procédé hautement efficace pour la purification et la production d'infliximab de recombinaison | |
| CN113584106B (zh) | 一种cho细胞表达的重组新型冠状病毒ncp-rbd蛋白的制备方法及其应用 | |
| CN103102417B (zh) | 一种重组人干扰素α2b-CTP融合蛋白的纯化方法 | |
| JP2007528195A (ja) | 高シアル酸含量のヒトトロンボポエチンを精製する方法 | |
| CN112979806A (zh) | 一种抗Her2抗体的制备方法 | |
| JPS6317898A (ja) | リンホトキシン類の精製法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |